CD12 is phase 3 (registrational) severe/critical trial. If the FDA balked at approval after successful completion of full trial, leronlimab would fly to the other three corners of the globe in a heartbeat.

The empty bag the FDA would be left holding would be insufficient to hide from the ensuing and pursuing angry mob.